Cardiff Lexington Corp Stock: price and insider trades · United States
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,000 shares0Common StockSEC:0001683168-26-002660:0
- 5,000 shares0Common StockSEC:0001683168-26-002657:0
- 5,000 shares0Common StockSEC:0001683168-26-002658:0
- 556,528 shares0Common StockSEC:0001683168-26-000671:0
- 62,500 shares0Common StockSEC:0001683168-26-000354:0
- 9,192,092 shares0Common StockSEC:0001683168-25-009171:5
- 5,000 shares0Common StockSEC:0001683168-25-009170:1
- 5,000 shares0Common StockSEC:0001683168-25-009168:1
- 270,000 shares0Common StockSEC:0001683168-25-009166:1
- 154,000 shares0Common StockSEC:0001683168-25-009166:2
- 2,496,834 shares0Common StockSEC:0001683168-25-009166:3
- 2,496,834 shares0Common StockSEC:0001683168-25-009166:4
- 10,073,092 shares0Common StockSEC:0001683168-25-009166:5
- 25,000 shares0Common StockSEC:0001683168-25-009169:1
- 5,000 shares0Common StockSEC:0001683168-25-009167:1
- 1,050,000 shares0Common StockSEC:0001683168-25-009171:2
- 270,000 shares0Common StockSEC:0001683168-25-009171:3
- 154,000 shares0Common StockSEC:0001683168-25-009171:4
- 10,000 shares0Common StockSEC:0001683168-25-009171:1
- 26,124 shares0Common StockSEC:0001683168-25-009171:0
- 5,000 shares0Common StockSEC:0001683168-25-009170:0
- 5,000 shares0Common StockSEC:0001683168-25-009167:0
- 1,050,000 shares0Common StockSEC:0001683168-25-009166:0
- 10,000 shares0Common StockSEC:0001683168-25-009169:0
- 5,000 shares0Common StockSEC:0001683168-25-009168:0
25 of 51 declarations
About Cardiff Lexington Corp
Cardiff Lexington Corp has a short record: 29 filings from seven filers, covering trades from October 30, 2018 to April 1, 2026, 25 of them in the last twelve months. No purchase appears. The only two sales are by David Lawrence Mccarthy, a holder of more than 10% of the capital, on October 30, 2018: EUR 13,185 and EUR 11,867, EUR 25,052 in all.
The rest of the record is made of 16 filings of another kind and 11 grants. Alex H. Cunningham (Chief Executive Officer) signs nine, Daniel Thompson (Chairman of the Board) six, and Louis Jack Staley Sr., Gillard B. Johnson III and Catherine B. Pennington, all three directors, three each.
Read moreShow less
This US healthcare company, whose insiders hold 60.6% of the capital, filed two reports in 2018, two in 2024, 20 in 2025 and five in 2026. The median publication delay is four days. None of the filings of the last twelve months involves a purchase or a sale.
